NEUTRAL / RISK-OFF UNDER THE SURFACE Friday's headline decline was modest, but the Russell fell 1.39%, AI infrastructure reversed sharply, quantum names dropped 5%–8%, the 2-year yield jumped to 4.34%, and Fed Chair Warsh said inflation progress remains insufficient.
Generated 08:35:29 CEST (Europe/Rome) / 06:35:29 UTC. Data cutoff 08:34 CEST. U.S., European and Asian figures are Friday Aug. 28 closes; Treasury yields are the official Aug. 28 curve. Weekend cash markets are closed and no live weekend indication is treated as executable. Saturday mode audits only calls published before Friday's session and maps the next 7–30 days.
Chair Warsh said inflation is above the Fed's 2% target, summer readings do not show meaningful trend improvement, and the Fed must be confident inflation is moving clearly and sufficiently quickly to target. The official curve closed at 4.34%/4.73% for 2Y/10Y. Fed speech · Treasury
NVDA −4.57%, VRT −4.53%, ANET −2.84%, CRDO −3.12% and MRVL −10.28%. NVIDIA's results remain exceptional, but Friday proved that strong demand evidence does not remove rates, valuation or expectations risk. Yahoo chart · NVIDIA results
Neutral-atom quantum company Pasqal began Nasdaq trading as PSQL after its business combination; it closed $19.11, +96.81% versus the prior $9.71 reference. This is a listing/liquidity event, not proof of commercial de-risking. SEC 6-K · Yahoo chart
| Prior call | Predefined condition / invalidation | Friday result | Audit verdict |
|---|---|---|---|
| VRT · #1 conditional bullish | Hold $267–269; tactical invalidation below $263. | $257.08, −4.53%; closed below invalidation. | Failed / stopped on paper Fundamental narrative did not protect the technical setup. No retroactive wider stop. |
| ANET · #2 conditional bullish | Reclaim $202.25; invalidation below $197. | $195.38, −2.84%; entry confirmation did not occur and close breached invalidation. | No entry / invalidated Correct discipline was to wait; it was not a valid long. |
| MRVL · #1 avoid/bearish failed reclaim | No open chase; bearish below $225/$220; invalid above $230 then $241.45. | $216.62, −10.28%; both bearish levels broke. | Confirmed Avoid thesis worked. Short execution cannot be assumed; opening gap reduced realizable asymmetry. |
| NVO · #2 avoid | No long until $47.20–47.50; further weakness below $46 worsens. | $45.61, −1.41%. | Confirmed avoid No reversal and structure weakened. |
| Watchlist · NVDA/AVGO/CRM/quantum/VKTX | No chase; require bases/level holds. | Only CRM rose (+1.57%); NVDA −4.57%, AVGO −0.74%, quantum −5% to −8%, VKTX −5.02%. | Caution validated CRM showed relative strength; the rest did not earn entries. |
Risk class: large-cap enterprise cloud, post-earnings gap/high volatility · Classification: relative-strength base only · Applicable horizon: day trade and 1–4 week swing; 3–12+ months only after recurring operating growth and FCF review. Direction uncertain.
Thesis/catalyst: CRM closed $256.00, +1.57%, after Thursday's 22.58% gap while Nasdaq fell 0.52%. The two-day hold makes it the only verified relative-strength survivor in the tracked AI/cloud basket.
Evidence / counterargument: Yahoo's intraday feed verifies the close; Friday breadth weakness raises the information value of relative strength. Counter: the move is still extremely extended, gap support can fail abruptly, and one-off investment gains should not be treated as recurring cloud revenue.
Entry/confirmation: require a calm base above $252–256 and a break of Friday's range with volume/market confirmation; do not chase a Monday gap. Invalidation/downside: close below $248, with $240 next; gaps can exceed levels. Key risks: valuation, rates, execution, AI monetization quality, competition and gap reversal. Yahoo chart
Risk class: newly listed de-SPAC/quantum, extreme price discovery and liquidity risk · Classification: avoid chasing; bearish only on confirmed failed rebound · Applicable horizon: day trade observation only; 1–4 week wait for structure; no 3–12+ month view without filings/fundamentals. Direction highly uncertain. Short risk is unlimited.
Thesis/catalyst: first-day close $19.11, +96.81% versus $9.71 reference, following the business-combination close. Such a move reflects listing/float dynamics as well as narrative demand and is not itself commercial validation.
Evidence / counterargument: SEC verifies listing and symbols; Yahoo verifies price. Counter: a scarce-float momentum squeeze could continue far beyond fundamentals, and genuine neutral-atom milestones could improve the thesis.
Entry/confirmation: no blind short. Bearish confirmation requires failed reclaim after a break below $17; safer stance is simply avoid. Invalidation/downside: bearish view invalid above $20.10 with sustained volume. Risks: unknown effective float here, halts, warrants, squeeze, dilution, early commercialization and limited price history. Borrow/fees not sourced. SEC · price
Risk class: speculative quantum, high valuation/cash-burn and event risk · Classification: avoid until stabilization; not an immediate short · Applicable horizon: 1–4 week watch; 3–12+ months only on commercial and unit-economics evidence. Direction uncertain. Short risk is unlimited.
Thesis/catalyst: IONQ fell 7.68% to $39.20 after Thursday's rebound. Its Aug. 28 8-K adds directors and addresses warrant expiration; it does not validate revenue, bookings, technical performance or fault tolerance.
Evidence / counterargument: SEC and Yahoo verify filing and price. Counter: a verified contract, hardware milestone or broad speculative rebound could reverse the decline sharply.
Entry/confirmation: no long until reclaim above $42.46 and positive basket breadth; avoidance strengthens below $38. Invalidation/downside: avoidance view expires above $44.86. Risks: cash burn, dilution, commercialization, architecture competition, rates, volatility and squeeze. Borrow/fees unknown. SEC 8-K · price
No second or third bullish idea and no third bearish idea: rate repricing and failed Friday follow-through leave poor asymmetry. Quotas are ceilings, not targets.
| Ticker / risk class | Classification & horizon | Thesis / catalyst / counterargument | Confirmation / invalidation / key risks | C / R / O |
|---|---|---|---|---|
| Watch AVGO Nasdaq · mega-cap custom silicon/networking, event gap | Sep. 2 earnings; day/swing only after results; 3–12 months on FCF/guidance. | $368.79, −0.74%. Key ecosystem read-through. Counter: high expectations; Nasdaq's $2.83 consensus is not guidance. | Wait for results and a base; above $372 constructive, below $360 weakens. Event gap, leverage, concentration, rates. | 79 / 96 / 63 |
| Watch NVDA Nasdaq · mega-cap, post-earnings/high expectations | Gap repair; day/swing after base; long term on growth/margins. | $217.55, −4.57%, surrendered much of Thursday's surge despite $108B guide. Counter: Q2 growth and ecosystem demand remain exceptional. | Reclaim $220 then $225; below $214 weakens. China/export policy, valuation, margin, rates, gap risk. | 91 / 91 / 58 |
| Watch VRT NYSE · large-cap/high-beta AI power/cooling | Broken setup; swing watch only after repair; long term on backlog/margins/FCF. | $257.08, −4.53%, violated prior $263 stop. Counter: structural data-center power demand remains plausible. | Reclaim $263 then $269; below $255 worsens. Capex timing, execution, valuation, rates. | 77 / 88 / 51 |
| Watch ANET NYSE · large-cap, high-valuation networking | Failed breakout; no swing until repair; long term on revenue/FCF. | $195.38, −2.84%, below prior $197 invalidation. Counter: networking demand could reaccelerate after AVGO results. | Reclaim $197 then $202.25; below $193 weakens. Concentration, competition, valuation, rates. | 73 / 85 / 49 |
| Watch LLY NYSE · mega-cap pharma, clinical/regulatory | Defensive relative-strength watch; 1–4 weeks; 3–12 months on franchise/data. | $1,174.61, −0.13%, beat thematic peers. TRIUMPH-2 completed, but registry has no posted statistics. Counter: valuation and binary data/safety risk. | Require healthcare-relative strength and reclaim $1,180; below $1,150 weakens. Trial efficacy/safety, reimbursement, competition, manufacturing. | 82 / 75 / 57 |
C / R / O = Thesis Confidence / Risk / Opportunity. Confidence measures evidence quality, never guaranteed outcome probability.
Monday bias: neutral/risk-off until breadth improves. CRM is the only conditional long, and only after a stable $252–256 base. Avoid chasing PSQL or shorting its first failure blindly.
Biggest risk: weekend gap or rate continuation. Invalidation: tactical risk-off eases if semis regain Friday ranges while 2Y/10Y yields retreat; it strengthens if Russell loses 2,970 and NVDA loses $214.
Bias: cash and selectivity before AVGO and FOMC. Broken AI charts must reclaim levels; quantum and small-cap biotech require evidence, not narrative.
Biggest risk: 4.73%+ 10Y and earnings expectation saturation. Invalidation: S&P strength accompanied by Russell/semiconductor breadth and repaired VRT/ANET structures would upgrade the regime.
Bias: favor profitable AI infrastructure after valuation/FCF work; demand commercial proof in quantum and full statistical/regulatory evidence in peptide biotech.
Biggest risk: sticky inflation forcing persistently high discount rates, peak capex, dilution or failed clinical endpoints. Invalidation: durable disinflation plus verified order/FCF acceleration would justify more duration exposure.